the reality of clinical trials in latin america€¦ · the cost of oncology medicines increased at...
TRANSCRIPT
The reality of Clinical Trials in Latin America
Christian Rolfo, MD, PhD, MBA, Dr.h.c.Professor of Medicine
Director of Thoracic Medical OncologyDirector of Early Clinical Trials
Marlene and Steward Greenebaum Comprehensive Cancer Center
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Current Landscape in Cancer:Contribution of Clinical Research
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
New Treatment and Trial Paradigm
35th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Number of Treatment Options over Time for Selected Tumors (1996-2016)
Global Oncology Trends 2017: Advances, Complexity, and Cost. QuintilesIMS Institute. June 2017.
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
The cancer treatment landscape has been transformed since 2011
Global Oncology Trends 2017. IQVIA report. https://www.iqvia.com/institute/reports/global-oncology-trends-2017-advances-complexity-and-cost
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
New drugs have significantly increased chances of survival
CancerNew therapies have contributed to significant declines in cancer death rates around the world since its peak in 1991. Today, 2 out of 3 people diagnosed with cancer survive at least 5 years1.
Percent Decline in Cancer Mortality Rates Since 1991 1991 to 2011 - All Cancers2
Source: Health Advances analysis; 1PhRMA 2016 Prescription Medicines: Costs in Context; 2WHO Mortality Database (accessed February 2016).
EU5
Australia
South KoreaJapanCanada
Mexico
-21%
-8%-21% -22%
-17%
-15%
USA
-24%
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Global clinical/Translational studies and trials by indication (%)
Global cancer research by type of study (%)
Liga D. Clinical Trails Conferences 2018.
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Oncology projected to be the biggest therapeutic area of the global pharma market in 2016
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Total global costs of oncology and supportive care therapies increased to $113 billion in 2016 at a rate of 11.6%
Global Oncology Trends 2017. IQVIA report. https://www.iqvia.com/institute/reports/global-oncology-trends-2017-advances-complexity-and-cost
The cost of oncology medicines increased at a compound annual growth rate (CAGR) of 11.0% since 2011, while the cost of supportive care treatments increased at CAGR of 2.0% in 2016.
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Dohll D. Pharmacoepidemiology and Clinical Research Congress 2017.
Global clinical/Biomedical cancer research investment growth in billions
CARG 44%/6.5 years
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
WELCOME TO A GOLDEN AGE OF CANCER DRUG DEVELOPMENT!!
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
The Traditional Drug Development Paradigm
Courtesy of David Hong
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
The Current Drug Development Paradigm
Courtesy of David Hong
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Trial duration and average enrollment have declined highlighting shifts in trial design and target indication size
Trial Duration and Patient Enrollment in Phase III Trials (1997–2016)
Clinicaltrials.gov, Feb 2017; QuintilesIMS Institute, Mar 2017
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
The era of Immunotherapy
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Immuno-Oncology PD-1 and PD-L1 Inhibitor Uptake
U.S. FDA, QuintilesIMS, National Sales Perspectives, Feb 2017; QuintilesIMS Institute, Apr 2017
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Next Generation Immuno-Oncology MoAs in Development
PD1/PDL-1 inhibitors have seen the greatest development across many of the existing tumor types
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Combinations of immuno- oncology products will increase the height of these waves.
Global Oncology Trends Report 2015. Report by the IMS Institute for Healthcare Informatics
The present /near future for IO treatments
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Pharmaceutical R&D expenditure in Europe, USA and Japan (millions of national currency units*), 1990–2015
European Federation of Pharmacautical Industries and Association Report 2016
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
hRMA, Annual Membership Survey 2016
Allocation of R & D investements by function (%)
European Federation of Pharmacautical Industries and Association Report 2016
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Pharmaceutical industry Research and Development in Europe
The cost of researching and developing a new chemical or biological entity
was estimated at € 1,926 million ($ 2,558 million in year 2013) in 2016
European Federation of Pharmacautical Industries and Association Report 2016
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Industry-Sponsored clinical trials in Europe
Note:Represents all clinical trials Phase 0 through Phase 4 that registered with Clinicaltrials.gov in 2015.
Source: Health Advances analysis; Clinicaltrials.gov (accessed February 2016).
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Decline of Clinical Trials in Central and Eastern Europe: Fluctuation or Trend?
• 66% of clinical trials are conducted in North America, Western Europe and Australia.
• However, other regions have arisen in recent years
Novak et al, Applied Clinical Trials Jun 16, 2014
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Best Countries For Oncology Clinical ResearchChina remains the top country overall, but Russia, Ukraine, Poland, and Romania rank close behind.North America and Western Europe rank third and fourth respectively, while the Middle East and Africa perform the worst with the lowest regional scores.
All these countries have relatively strong infrastructures for Oncology, but really outperformed other countries with their strong recruitment rates and access to patients.
The scenario can change...
(excluding Japan from the analysis)KMR Group Data, Applied Clinical Trials 02 December 2016
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
2015 Availability of New Oncology Medicines Launched 2010-2014
IMS Health, MIDAS, Q4 2015, IMS Institute for Healthcare Informatics, May 2016
Canada
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
2015 Availability of Oncology Medicines Launched 2010-2014 within the EU and Eastern Europe
IMS Health, MIDAS, Q4 2015, IMS Institute for Healthcare Informatics, May 2016
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Cancer Clinical Trials 04/04/2019: 17212 Studies
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
CT ́s of cancer through the Years
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Pantents Granted
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
What type of Clinical Research?
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Trials Sponsorship in Emerging Regions
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Regulatory aspects of Clinical Trials in LATAM
Investigator Support Pharma Support
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Time to regulatory authority approval according to geographical (A) and economic (B) regions.
Metzger-Filho O et al. The Oncologist 2013;;18:134-140
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Analysis of Regional Timelines Time to regulatory authority (RA) approval, defined as the
time interval between protocol submission by the sponsor to the RA and its approval
Metzger-Filho O et al. The Oncologist 2013;;18:134-140
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Efficiency Gain From A Thoughtful Scientific/Regulatory Strategy
Unoptimized Strategy
Phase I
Phase II
Phase III
Preclinical
Toxicology
Patent
lifeRegulatory
Filing
Phase III
Phase II
Phase I
Preclinical
Toxicology
Discovery
Time (Years)
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Efficiency Gain From A Thoughtful Scientific/Regulatory Strategy
41
Time (Years)
Patent
lifeRegulatory
Filing
Phase I
Phase III
Preclinical
Toxicology
Phase II
Discovery
Accelerated Approval
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
SCIENTIFIC PRODUCTION OF LATAM: IT’S POSIBLE??
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
The Globalization of Clinical Investigators
Percent of total
Tufts CSDD 2015
20155th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Despite myriad problems in many countries, pockets of excellence thrive in South American science.
• Science in Brazil and many other countries in South America has come a long way since the dark days of the dictatorships just a generation ago.
• In Argentina, the number of science doctorates jumped nearly ten fold between 2000 and 2010
• Peruvian scientists tripled the tally of articles they produced over the same period; and science funding is climbing in most countries.
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Distribution and trends of hematology and oncology research in Latin America: A decade of uncertainty
Acevedo A, et al. Cancer. 2014 Apr 15;120(8):1237-45.
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Country Ranking according
to full-text
publications
Total abstracts
presented
Later publication of
abstract
as a full-text report†
Time to full-text
publication
in years
n % Median (range)
Brazil 1 1008 212 (21) 2 (0-7)
Mexico 2 279 54 (19.4) 1 (0-8)
Argentina 3 387 43 (11.1) 1 (0-7)
Chile 4 50 11 (22) 1 (0-3)
Peru 5 122 10 (8.2) 0.5 (0-3)
Cuba 6 27 9 (33.3) 2 (0-3)
Venezuela 7 25 6 (24) 1.5 (1-4)
Uruguay 8 32 3 (9.4) 0 (0-7)
Colombia 9 25 3 (12) 0.5 (0-1)
Costa Rica 10 4 2 (50) 3.5 (2-5)
Panama N/A 5 0 N/A
Total 1972 353 (17.9) 1 (0-8)Acevedo A, et al. Cancer. 2014 Apr 15;120(8):1237-45.
Distribution and trends of hematology and oncology research in Latin America: A decade of uncertainty
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Distribution and trends of hematology and oncology research in Latin America: A decade of uncertainty
All LATAM countries
Brasil
Argentina
México
Acevedo A, et al. Cancer. 2014 Apr 15;120(8):1237-45.
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
2 0 2 | N AT U R E | VO L 5 1 0 | 1 2 J U N E 2 0 1 4
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
HOW TO OVERCOME THIS SITUATION??
Becaming more attractive for Clinical Trials!
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Recruitment potentialRegion Number
Studies analyzed
# of recruited subjects
% recruited patients
Patients per million citizens
LATAM 161 23.341 7.5% 46
USA 181 40.433 12.9% 133
Australasia 185 9.653 3.1% 140
UK 173 16.873 5.4% 276
Canada 191 14.695 4.7% 442
Leem Recherche, Clinique Internationale Enquete 2010.
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Value of Inter-Institutional clinical projects
• Improved access of patients and professionals to the local and international experts/knowledge
• Increased communication and hence learning among all participants (community of practice)
• May identify problems that are specific to populations, regions or institutions
J Clin Epidemiol. 2012;65(5):482-7.
If you are trying to start cancer research in Latin America:1. Do outcome research (real clinical scenarios)2. Design population based data bases3. Increase effective networking 4. Use mentorship5. Use operative data management 6. Improve medical writing 7. Protect time to be creative 5t
h ESO-E
SMO L
atin
Amer
ican
Mas
terc
lass i
n Clin
ical O
ncolo
gy
The survey was completed by 6931 members of the public, over 75% of whom
reported having no or less than good knowledge of medicines R&D.
What the public knows and wants to know about medicines research and development: a survey of the general public in six European countries
Parsons S, et al. BMJ Open 2015;5:e006420.
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Patient Enrollment in Oncology Phase I Clinical Trials
Van Der Biessen D. et al, The Oncologist 2013;18:323–329
• 44% of all patients who were in-
formed about a specific phase I trial
eventually participated.
• Reasons for both participation and non
participation were diverse.
• Patient participation rates could be
improved by forming an experienced
and dedicated study team.
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Fashion
Power
Business
More and more ‘’market and regulatory oriented’’ and
less patients directed or based on unmet need in
diseases or settings!
Current strategy of clinical research is dominated by:
Modified from A. Awada
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
YES NO
• Several new anticancer agents reached clinical practice
• Often improvement in PFS but rarely in survival
•Redundancy in the development of agents
•Many competitive trials in the same setting
•Few studies looking to a therapeutic strategy
•Few studies in unmet need clinical settings•More and more biomarkers studies butlimited validated biomarkers for clinical use
Still a huge gap between clinical research & the need in clinical
practice
Does the current design of oncology trials meet the need of patients?
Courtesy of A. Awada
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Regulation of the European Parliament and of The Council on Clinical Trials on Medicinal Products for Human Use, repealing Directive 2001/20/EC
• The scope of the Regulation is extensive, with several primary components
• covered in the core text and multiple appendices, including:
• Authorization procedures
• Start of trial, suspension or temporary holds, early termination
• Protection of subjects, informed consent
• Conduct of trials
• Safety reporting
• IMP manufacturing, labeling and import
• Insurance
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Genotype driven
Basket trialsTest the effect of one or more drugs on one or more single mutation in a variety of cancer types
UmbrellaTest the impact of different drugsin different mutations in a single type of cancer
New designs
Adaptative trialbased on modifying parameters of a clinical trial evaluating a treatment according to outcomes in participants
N of 1Assessing the administration of an investigational agent over a short period of time
Windows of opportunity
Assessing the administration of an investigational agent over a short period of time
Selected new designs in drug development
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Partnership and Funding
People LabsCash Consumables
Source: Health Advances analysis; 1IMI website; 2EFPIA 2014 Annual Report.
€1,638BILLION
€1,425EFPIA direct and indirect
member companies
€213Other sectors
€3,276
€1,638BILLION
€3,276BILLION2014-2024
€1,638From Horizon 2020
PRIVATE IN KINDCONTRIBUTION
PRIVATEPARTNERS
PUBLICPARTNERS
PUBLIC
CASH for grants for PUBLIC PARTNERS
PRIVATE PARTICIPATION
Biopharmaceutical Innovation
IMI 2 Partnership and Funding Overview2
The Innovative Medicines Initiative
(IMI) is the world's largest public-private partnership
IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
Through the IMI 2, a joint undertaking between the European Union and the pharmaceutical industry association EFPIA, a
€3.3 billion budget for the period 2014-2024 has been established.
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
: A New Clinical Research Network
A network of 8 comprehensive cancer centers and 13 university
hospitals and academic centers dedicated to oncology care and
research.
•University Hospital Brussels Belgium
•Institut Jules Bordet Brussels Belgium
•Antwerp University Hospital Belgium
•CHU Ambroise Paré, Mons Belgium
•Saint Elisabeth, Namur Belgium
•Centre Hospitalier de Luxembourg
•Oslo University Hospital Norway
•Erasmus MC Rotterdam Netherlands
•Centre Oscar Lambret, Lille France
•CHU Rouen France
•CHU Strasbourg France
•Hopital Saint Louis Paris France
•Centre Georges-François Leclerc Dijon France
•Institut Claudius Rigaud Toulouse France
•Institut Paoli Calmette Marseille France
•Institut Curie Paris France
•Hopital Paris Saint Joseph France
•Val d’Hebron Madrid Spain
•Istituto Nationale dei Tumori Milan Italy
•American University of Beirut Lebanon
•Anhui Medical University Hospital China
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
olacancer.org
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Molecular Tumor Board
Patient case is derived from his doctor
Mol. Pathol PediatGeneticistOncologist Gyneco Thorax
Molecular Tumor BoardReport with therapeutic
proposal
Referral Doctor Discussion
Nav. nurse
New tools like Molecular Tumor Boards
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
More infrastructure …..
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Translational Reserach….
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Increasing the Recruitment Startegies
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
EXAMPLE OF SUCCESS IN LATAM
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Colombia (24.7%)N 1.939/EGFR+ 479
Argentina (14.4%)N 1.713/EGFR+ 247
Perú (51%)N 300/EGFR+ 200
México (34.3%)N 1.417/EGFR+ 486
Latin America (26%)N 5.738/EGFR+ 1.492
Up
dat
ed f
req
uen
cy o
f EG
FR a
nd
KR
AS
mu
tati
on
s in
NSC
LC in
Lat
in
Am
eric
a: C
LIC
aP
Costa Rica (31.4%)N 102/EGFR+ 32
Panama (27.3%)N 174/EGFR+ 48
Population
- Female 52.6%
- Tobacco exposure 51%
- Adenocarcinoma 95.1%
- K-Ras 7.1% (N 2385/184)
Arrieta O, et al. J Thorac Oncol. 2015 Jan 28. [Epub ahead of print]
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Latin America N= 4,136
Positive 6.09% (252)
Negative 93.91% (3,884)
FISH- ALK in Non-Small Cell Lung Cancer
Colombia
4.1%
(10/242)
Chile
5.2%
(5/94)
Argentina
6.1%
(153/2491)
Uruguay
5.3%
(2/37)
Panama
4.4%
(5/114)
Mexico
8.3%
(64/769)
Costa Rica
8.7%
(13/137)
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Patiño, Cardona, Arrieta, Rolfo et al, in press
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
International collaboration in the scientific production (Scopus) on cancer with at least one author affiliated to an institution in Colombia, Quantitative (2013-2017)
Bravo-Linares D, Ruiz-Patiño A, Lucio D, Cardona AF. Unpublished data (ACHO 2018).
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Collaborative networks in the scientific production on cancer (WoS) with at least one researcher affiliated with an institution in Colombia
Bravo-Linares D, Ruiz-Patiño A, Lucio D, Cardona AF. Unpublished data (ACHO 2018).
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Latin America Authorship Network
Patiño, Cardona, Arrieta, Rolfo et al, in press
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
This is a Race!
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
LATAM Europe Est Asia USA
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
▪We are no the worst! We have an incredible potential bur It’s a very competitive world!
▪Strategies to implementation of attractive approaches are needed.
▪Harmonization among all LATAM countries is mandatory
▪Networking and Education are crucial!
▪Advocacy groups are a great resource
Key Messages:
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
79
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
olacancer.org
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology
Thanks [email protected]
@ChristianRolfoThanks to Dr. Andrés Cardona and Dr. Henry Gómez
5th
ESO-ESM
O Lat
in Am
erica
n M
aste
rclas
s in
Clinica
l Onc
ology